McPhersons (ASX:MCP) - Resigned CEO & Managing Director, Laurie McAllister
Resigned CEO & Managing Director, Laurie McAllister
Source: The CEO Magazine
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Laurie McAllister has resigned as CEO and Managing Director of McPherson’s (MCP), effective December 9
  • Laurie has led the health and wellness company over the past four years and MCP says he leaves the company in a strong position for future growth
  • One of his highlights is the successful acquisition of Global Therapeutics in NSW
  • In the interim, Non-Executive Director Grant Peck will replace Laurie to aid in the transition to a more permanent holder
  • McPherson’s will now begin the steps to appoint a more permanent CEO and Managing Director and will provide further announcements in due course
  • Company shares are down 6.8 per cent and are trading at $1.17

Laurie McAllister has resigned as CEO and Managing Director of McPherson’s (MCP), effective December 9.

Laurie has led the health and wellness company over the past four years and MCP says he leaves the company in a strong position for future growth.

One of his highlights is the successful acquisition of Global Therapeutics in Byron Bay, NSW.

Before joining McPherson’s, Laurie worked at Coca-Cola for 23 years, where he had a stint as the Chief Commercial & Marketing Officer for Japan.

Laurie will remain available for a short period of time to assist McPherson’s executive team if required.

In the interim, Non-Executive Director Grant Peck will replace Laurie, effective December 10. This will provide continuity and aid in the transition to a more permanent holder.

Grant has been a Non-Executive Director since December 2017 and is also a member and Chairman of McPherson’s Audit, Risk Management and Compliance Committee.

McPherson’s will now begin the steps to appoint a more permanent CEO and Managing Director and will provide further announcements in due course.

Company shares are down 6.8 per cent and are trading at $1.17 at 2:10 pm AEDT.

MCP by the numbers
More From The Market Online
The Market Online Video

Many are concerned about global falling birthrates. This diverse stock has solutions

Outside of US politics, there is one issue that’s been popping up more and more across…
Diabetes concept

Proteomics notches up as company launches PromarkerD into the US

Proteomics (ASX:PIQ) has seen shares pop just over +4% in early Friday trades after launching its…
Australian currency cash

Recce locks in $30M to boost commercialisation across ASEAN region

Recce Pharmaceuticals (ASX:RCE) has secured the first tranche of a $30M debt facility to continue running…
Huntington's Disease representation

This stock is crafting a cure for Huntington’s – and it’s making progress

Neurizon Therapeutics (ASX:NUZ) has declared that its in-house product NUZ-001 Sulfone granted neuroprotective effects...